Actively Recruiting
Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)
Led by Czech Lymphoma Study Group · Updated on 2017-06-26
20000
Participants Needed
1
Research Sites
1513 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The Czech National Lymphoma Registry (NiHiL) was founded to monitor epidemiologic data and improve the diagnostic evaluation and quality of treatment of patients with non-Hodgkin´s lymphoma (NHL). The patients are registered into the registry in anonymized form. For each patient are available: registration form, diagnostic form, treatment form, follow- up form, and other malignancy form. Data quality in the NiHiL has been checked by audits. The data is analyzed according to NHL subtypes with endpoints: lymphoma distribution, epidemiological data, prognostic characteristic, treatment characteristics, response rate, relapse rate, mortality, PFS, OS, DFS, Lymphoma specific survival, longterm toxicity.
CONDITIONS
Official Title
Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- lymphoma diagnosis
- treated in the Czech Republic
- signed informed consent
You will not qualify if you...
- unsigned informed consent
- age <18 y
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Charles University General Hospital
Prague, Czechia, 128 08
Actively Recruiting
Research Team
M
Marek Trneny, prof. MD
CONTACT
D
David Belada, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here